OGN Stock News: Robbins LLP Reminds Organon & Co. Investors of the Pending Lead Plaintiff Deadline in the OGN Class Action – Contact Robbins LLP Before July 22 for Information

Core Viewpoint - A class action lawsuit has been filed against Organon & Co. for allegedly misleading investors regarding its capital allocation strategy, particularly concerning its debt reduction efforts and dividend payouts [1][2][3]. Allegations - The lawsuit claims that during the class period, Organon misrepresented its commitment to regular dividends as its "1 capital allocation priority," while concealing the importance of its debt reduction strategy following the acquisition of Dermavant [2][3]. - The complaint highlights that the company reduced its regular quarterly dividend by 70%, from $0.28 to $0.02, which was not disclosed to investors during the class period [3]. Impact of Disclosure - The truth about the company's financial strategy was revealed on May 1, 2025, when Organon announced its first quarter results, leading to a significant drop in its stock price from $12.93 to $9.45, a decline of over 27% [4].